Polyethylenimine shows properties of interest for cystic fibrosis gene therapy
Stefano Ferrari(University of Padua), Maurizio Scarpa(University of Udine), Andrea Pettenazzo(University of Padua), Nicoletta Garbati(University of Padua), Franco Zacchello(University of Padua), Jean‐Paul Behr(Laboratoire de Chimie)
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
October 1, 1999
Cited by 103
Related Papers
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse
|The Journal of Gene Medicine|2000|313
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302